Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adipose dreived allogeneic stem cell therapy - Regeneus

Drug Profile

Adipose dreived allogeneic stem cell therapy - Regeneus

Alternative Names: PRG; Progenza™

Latest Information Update: 21 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneus ltd
  • Class Mesenchymal stem cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Cytokine stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Osteoarthritis
  • Preclinical Neuropathic pain

Most Recent Events

  • 20 Jul 2023 Preclinical development is ongoing for Neuropathic pain in Australia (Regeneus pipeline, July 2023)
  • 02 Jan 2023 Adipose dreived allogeneic stem cell therapy is still in phase-II clinical trials for Osteoarthritis in Australia (Intra-articular) (Regeneus pipeline, January 2023)
  • 05 Aug 2021 Regeneus and Genome Institute of Singapore enters into R&D agreement to improve efficiencies in adipose tissue donor selection
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top